Startup profile · funding coverage
Amber funding, valuation and investors
RNA-based multi-kilobase gene editing platform for diseases with high allelic diversity.
Keep track of Amber
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$26M · August 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$26M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · San Francisco, California
Investors in latest funding
Other: Andreessen Horowitz
Overview
Amber Bio (amber.bio) develops Cas-based RNA writing tools that enable kilobase-scale edits on RNA strands. Co-founders Jacob Borrajo and Basem Al-Shayeb (Broad Institute and UC Berkeley gene-editing backgrounds) aim to treat genetically heterogeneous diseases with a single therapeutic rather than one program per mutation.
Why Amber is interesting
Amber Bio edits RNA instead of DNA for reversible, multi-kilobase corrections — Broad/Berkeley founders targeting mutation-diverse diseases where one drug can cover many variants.
Product & use cases
Amber Bio (amber.bio) develops Cas-based RNA writing tools that enable kilobase-scale edits on RNA strands.
- Primary product use case per company site
- Enterprise or consumer deployment
Key facts
- Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
- Platform: multi-kilobase RNA editing for allelic-diverse genetic diseases (Amber Bio site)
- Co-investors not in VCT directory: Playground Global, Eli Lilly, RDF, Hummingbird Ventures, Pillar VC
Funding history (newest first)
Seed
Aug 2023 $26MSource: Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
Unknown
Source: Co-investors not in VCT directory: Playground Global, Eli Lilly, RDF, Hummingbird Ventures, Pillar VC
Investors in our directory
Funds linked from Amber's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Amber Bio edits RNA instead of DNA for reversible, multi-kilobase corrections — Broad/Berkeley founders targeting mutation-diverse diseases where one drug can cover many variants.
Amber competes in biotech-life-sciences. Incumbents have distribution; startup edge depends on product depth and buyer references. See competitors for specific tradeoffs — no invented market share claims.
-
Veeva incumbent
Life sciences cloud incumbent.
-
Dotmatics adjacent
R&D informatics.
Notable stories
- Seed (Aug 2023): $26M co-led by Playground Global and a16z Bio + Health; ARCH Venture Partners, Eli Lilly, RDF, Hummingbird, Pillar VC participated (Business Wire)
- Platform: multi-kilobase RNA editing for allelic-diverse genetic diseases (Amber Bio site)
Industries
Related funding articles
Venture Capital Tracker pieces that cover Amber's financing or category context.
FAQs about Amber
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.